From Startup Brainstorm Cell Therapeutics
Link to Full Article: http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-newsArticle&ID=2358615
NEW YORK and PETACH TIKVAH, Israel, July 17, 2018 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the second quarter ended June 30, 2018, and provide a corporate update, on Monday, July 23 at 8:30am Eastern Time.
Conference Call – Monday, July 23rd @ 8:30am Eastern Time
USA Toll Free:
1809 212 883
Replays, Available through August 6th:
About BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases.
The Company has developed the NurOwn® technology into a commercially viable product. NurOwn® has been already administered to over 70 patients with ALS in clinical trials conducted in the United States and in Israel. In a randomized, double blind, placebo-controlled clinical trial conducted in the U.S., a clinically meaningful benefit was demonstrated by higher response to NurOwn® compared with placebo. The Company is currently conducting a Phase 3 double blind, placebo-controlled clinical trial at multiple clinical sites throughout the US. For more information, visit the company’s website at www.brainstorm-cell.com.
Safe-Harbor Statement Statements in this announcement other than historical data and information constitute “forward-looking statements” and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.’s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as “may”, “should”, “would”, “could”, “will”, “expect”, “likely”, “believe”, “plan”, “estimate”, “predict”, “potential”, and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm’s limited operating history, history of losses; minimal working capital, dependence on its license to Ramot’s technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm’s annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm’s forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
CONTACTSUri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: email@example.com
Investors:Michael RiceLifeSci Advisors, LLCPhone: firstname.lastname@example.org
Media: Drew Levinson LifeSci Public Relations Phone: 917-797-0388 email@example.com
View original content with multimedia:http://www.prnewswire.com/news-releases/brainstorm-to-announce-second-quarter-financial-results-of-2018-and-provide-a-corporate-update-on-monday-july-23-300682092.html
SOURCE BrainStorm Cell Therapeutics Inc.
Please visit their site for more information: Brainstorm Cell Therapeutics.com
All,Biotechnology,Healthcare News,Startup News